What is Mevrometostat?: An In-Depth Look at a Novel Cancer Therapy
•
4 min read
In early 2025, clinical trial data showed that Mevrometostat combined with enzalutamide reduced the risk of disease progression or death by 49% in some prostate cancer patients. **What is Mevrometostat?** It is an investigational EZH2 inhibitor being developed by Pfizer for advanced prostate cancer.
